FOLH1 and neoplasm: Despite some initial disappointment and lessons learned with use of FDG PET and PET/CT for evaluating PCa 64, precise comprehension of tumor biology and appropriate patient selection have provided valuable knowledge, allowing the rational use of this technology for selected indications 65, and, more importantly, have paved the way for molecular imaging with others tracers (i.e., 18F-choline and 18F/68Ga-PSMA) for PCa evaluation, specifically in assessment of therapeutic responses.